지노믹트리

228760KOSDAQ

44.5 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

GenomicTree is a South Korean company specializing in early cancer detection using biomarker-based molecular diagnostics, with its flagship product 'EarlyTect-Colon Cancer' approved in 2018. The test uses stool DNA and offers high sensitivity and rapid results, competing with traditional colonoscopies. The company is expanding globally through subsidiaries in the U.S. and a joint venture in China, though 2024 revenue declined due to the end of its coronavirus diagnostic business.

Number of Employees

76people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.27Industry Average 1.201.0Point

1.9x industry avg (risky)

ROE

-7.62Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.87Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 10,550Won52-week high 32,00052-week low 10,280

1-month return0.0Point

1m -16.93% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-08-20
Neutral반기보고서 (2026.06)2026-08-14